TTR and familial amyloid neuropathy: Inotersen, on the other hand, is indicated for the treatment of hereditary transthyretin amyloidosis (hATTR) and targets the mRNA of transthyretin (TTR) [20], preventing the abnormal extracellular deposition of TTR proteins that give rise to hATTR.